Global Oncology Molecular Diagnostics Market to Grow at 12.37% During 2025-2033, Fostered by Growing Awareness Regarding Early Cancer Detection

December 27, 2024 | Healthcare

According to the latest report by IMARC Group, titled "Oncology Molecular Diagnostics Market Report by Cancer Type (Breast Cancer, Prostate Cancer, Colorectal Cancer, Cervical Cancer, Liver Cancer, Lung Cancer, Blood Cancer, and Others), Product (Instruments, Reagents, and Others), Technology (Polymerase Chain Reaction (PCR), In Situ Hybridization, Chips and Microarrays, Isothermal Nucleic Acid Amplification Technology (INAAT), Mass Spectrometry, DNA and NGS Sequencing, Transcription Mediated Amplification (TMA), and Others), End-User (Hospitals and Clinics, Reference Laboratories, and Others), and Region 2025-2033," the global oncology molecular diagnostics market reached a value of USD 4.8 Billion in 2024. Oncology molecular diagnostics is a part of laboratory medicine that involves analyzing biological markers for the detection of cancer cells in an individual. In this process, blood, saliva, and tumor tissue sample tests are performed on the patient for measuring specific genetic sequences in the DNA, RNA and cell proteins. They are utilized for performing rapid analysis of the condition and providing detailed critical information regarding it. The quantitative measurements offered by the diagnostics are essential in understanding the stage and available effective therapeutic options for cancer. This aids in determining the right course of personalized treatment for the patient by making informed medical decisions for a better outcome.

Global Oncology Molecular Diagnostics Market Trends:

The market is primarily driven by the growing prevalence of different forms of cancer across the globe. This can be attributed to the sedentary lifestyles led by the majority of the population, along with the high tobacco and alcohol uptake by the masses. Consequently, there is a significant increase in the demand for efficient diagnostic solutions, thereby providing a thrust to the market growth. Apart from this, the rising awareness regarding early cancer detection among individuals is acting as another major growth-inducing factor. Moreover, there has also been a considerable increase in the geriatric population on the global level. This, along with the growing investments by numerous private and public organizations to develop the oncology infrastructure across healthcare facilities, is creating a positive outlook for the market. Numerous players have also introduced technologically advanced diagnostics products in the market. Since these products offer enhanced accuracy and speed in terms of diagnosis while being affordable, they are gaining widespread prominence across the healthcare sector. Some of the other factors catalyzing the market growth include the increasing penetration of healthcare insurance in numerous developing countries and the rising trend of medical tourism on the global level. Looking forward, the market value is projected to reach USD 14.3 Billion by 2033, expanding at a CAGR of 12.37% during 2025-2033.

Marker Summary:

  • On the basis of the cancer type, the market has been divided into breast, prostate, colorectal, cervical, liver, lung, blood and other forms of cancer.
  • Based on the product, the market has been classified into instruments, reagents and others.
  • On the basis of the technology, the market has been categorized into polymerase chain reaction (PCR), in situ hybridization, chips and microarrays, isothermal nucleic acid amplification technology (INAAT), mass spectrometry, DNA and NGS sequencing, transcription mediated amplification (TMA) and others.
  • Based on the end-user, the market has been segmented into hospitals and clinics, reference laboratories, and others.
  • On the geographical front, the market has been segregated into North America (the United States and Canada), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia and others), Latin America (Brazil, Mexico and others), and Middle East and Africa.
  • The competitive landscape of the market has been studied in the report with the detailed profiles of the key players. Some of these players include Agilent Technologies, Inc., Abbott Laboratories, Bayer AG, Becton, Dickinson and Company, Danaher Corporation, F. Hoffmann-La Roche AG, Hologic, Inc., Qiagen N.V., Siemens Healthcare and Sysmex Corporation.


Report Coverage:

Report Features Details
Base Year of the Analysis 2024
Historical Period 2019-2024
Forecast Period 2025-2033
Units Billion USD
Segment Coverage Cancer Type, Product, Technology, End-User, Region
Region Covered  Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered Agilent Technologies, Inc., Abbott Laboratories, Bayer AG, Becton, Dickinson and Company, Danaher Corporation, F. Hoffmann-La Roche AG, Hologic, Inc., Qiagen N.V., Siemens Healthcare and Sysmex Corporation
Customization Scope 10% Free Customization
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)


About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group
30 N Gould St, Ste R
Sheridan, WY (Wyoming) 82801 USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Global Oncology Molecular Diagnostics Market to Grow at 12.37% During 2025-2033, Fostered by Growing Awareness Regarding Early Cancer Detection
Purchase Options New Year Sale
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials